**DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011;34:789--794**

In the "Pharmacokinetics and Dose" section (page 790) of the article listed above, the starting dose should have been 0.8 mg/day, rather than 0.8--1.6 mg/day, and the maximum dose should have been 4.8 mg/day, rather than 4.6 mg/day.

The legend for Fig. 3 should have read as follows: "Top: Kaplan-Meier plot of time to first cardiovascular (MACE) event (myocardial infarction, stroke, and death) in type 2 diabetic subjects treated with Cycloset or placebo for 52 weeks (ref. 41). Bottom: Kaplan-Meier plot of time to first cardiovascular event (myocardial infarction, stroke, hospitalization for angina or CHF, coronary revascularization, and death) in 3,070 type 2 diabetic subjects treated with Cycloset or placebo for 52 weeks (ref. 42). CVEs, cardiovascular events."

The hazard ratio (HR) for the top curve in Fig. 3 should have been 0.45, rather than 0.55, and the 95% CI should have been 0.205--0.996, rather than 0.39--0.98.

On page 793, the sentence "Using the major adverse cardiac events (MACE) end point (myocardial infarction, stroke, and death), the HR was reduced in the Cycloset compared with placebo-treated subjects (HR 0.55, two-sided 95% CI 0.39--0.98, *P* \< 0.05) (Fig. 3)" should have read "Using the major adverse cardiac events (MACE) end point (myocardial infarction, stroke, and death), the HR was reduced in the Cycloset compared with placebo-treated subjects (HR 0.45, two-sided 95% CI 0.205--0.996, *P* \< 0.05) (Fig. 3)."

In Supplementary Fig. 5, the fasting TG values for each bar should have read as follows:
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